Pioneer Investment Management Inc. lowered its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 25.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,594 shares of the biopharmaceutical company’s stock after selling 27,754 shares during the period. Pioneer Investment Management Inc.’s holdings in Bristol-Myers Squibb were worth $4,491,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in the company. Waldron LP purchased a new stake in shares of Bristol-Myers Squibb during the first quarter worth about $475,000. IFP Advisors Inc increased its stake in shares of Bristol-Myers Squibb by 5.5% during the first quarter. IFP Advisors Inc now owns 92,923 shares of the biopharmaceutical company’s stock valued at $5,053,000 after purchasing an additional 4,812 shares in the last quarter. Leavell Investment Management Inc. increased its position in shares of Bristol-Myers Squibb by 3.1% during the first quarter. Leavell Investment Management Inc. now owns 21,471 shares of the biopharmaceutical company’s stock valued at $1,168,000 after acquiring an additional 650 shares in the last quarter. Breton Hill Capital Ltd. bought a new stake in shares of Bristol-Myers Squibb during the first quarter valued at approximately $1,335,000. Finally, Oakworth Capital Inc. increased its position in shares of Bristol-Myers Squibb by 3.7% during the first quarter. Oakworth Capital Inc. now owns 10,830 shares of the biopharmaceutical company’s stock valued at $589,000 after acquiring an additional 385 shares in the last quarter. 68.90% of the stock is currently owned by hedge funds and other institutional investors.
BMY has been the topic of several analyst reports. Barclays PLC upped their price target on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an “equal weight” rating in a report on Friday, October 13th. Jefferies Group LLC cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price target for the company. in a research report on Monday, October 16th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 12th. Leerink Swann upped their price target on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday. Finally, Citigroup Inc. increased their target price on shares of Bristol-Myers Squibb to $72.00 and gave the company a “buy” rating in a research report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $64.53.
Shares of Bristol-Myers Squibb Company (NYSE BMY) traded down 0.87% during midday trading on Friday, reaching $60.42. 1,892,312 shares of the company were exchanged. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The firm’s 50 day moving average is $63.60 and its 200-day moving average is $57.54. The company has a market capitalization of $99.08 billion, a PE ratio of 22.07 and a beta of 1.19.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.77 earnings per share. On average, equities analysts forecast that Bristol-Myers Squibb Company will post $2.99 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.56%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 56.73%.
ILLEGAL ACTIVITY NOTICE: “Pioneer Investment Management Inc. Sells 27,754 Shares of Bristol-Myers Squibb Company (BMY)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/10/27/bristol-myers-squibb-company-bmy-shares-sold-by-pioneer-investment-management-inc.html.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at $2,777,820. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, August 2nd. The shares were purchased at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the acquisition, the director now owns 18,000 shares in the company, valued at $1,006,920. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.